Mylan launches digital adherence programme for heart patients
pharmafile | November 27, 2015 | News story | Medical Communications | Canada, Mavik, Mylan, pharmacies, trandolapril
Mylan has launched an innovative digital medication adherence and engagement program for patients with high blood pressure.
The digital programme, called MyFreshStart, is for patients taking trandolapril blood pressure tablets, which the firm markets as Mavik in Canada, where the program will be launched.
The MyFreshStart program, which is offered to patients with hypertension through participating pharmacies, provides tools to help increase compliant behaviours such as maintaining prescription refills and taking Mavik as prescribed.
Barry Hayter, head of Mylan in Canada says: “We’re excited to announce the launch of MyFreshStart for pharmacists and their patients. We know that non-adherence negatively impacts health outcomes, and we believe this program provides pharmacists with a meaningful platform to discuss the importance of compliance with their patients. This new resource reinforces Mylan’s commitment to expand access to high quality medicine as we innovate to meet unmet needs.”
Developed with support from US-based HealthPrize Technologies, MyFreshStart seeks to educate patients about high blood pressure, and how they can better manage it through engaging activities such as quizzes, daily fortunes, leaderboards and sweepstakes.
Once enrolled in MyFreshStart through a participating pharmacy, patients can access the platform to begin earning points that can be redeemed for health-related items.
Mylan is offering MyFreshStart at no cost to pharmacies in Canada, which serve as the primary provider of patient enrolment for the program, and looks forward to continue partnering with pharmacists as key drivers of patient engagement and empowerment.
Yasmita Kumar
Related Content
NHS-integrated pharmacy app Charac receives £1.2m funding
Charac, an NHS-integrated pharmacy app, has raised £1.2m in debt and equity financing from the …
Pfizer to pay $345 million in EpiPen lawsuit
Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as …
Canada first country to authorise Pfizer vaccine in children aged 12-15
Canada has become the first country to authorise the use of Pfizer’s COVID-19 vaccine for …
